JNJ 39393406

Drug Profile

JNJ 39393406

Alternative Names: JNJ-39393406

Latest Information Update: 07 Feb 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Janssen Pharmaceutica
  • Developer Janssen Pharmaceutica; National Institutes of Health (USA); University of Pittsburgh
  • Class Antidementias; Nootropics
  • Mechanism of Action Alpha7 nicotinic acetylcholine receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Depressive disorders; Smoking withdrawal
  • Discontinued Alzheimer's disease; Schizophrenia

Most Recent Events

  • 15 Feb 2016 Johnson & Johnson Pharmaceutical Research plans the exploratory phase II JNJ-DEP trial for Depressive disorders in Romania (PO, Capsule) (NCT02677207)
  • 01 Feb 2016 Phase-II clinical trials in Depressive disorders in Romania (PO) (NCT02677207)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top